|
Exchange Disseminated Time | Caplin Point Laboratories Ltd has informed BSE that:
A license and distribution agreement has been made and entered by and between Caplin Point Laboratories Limited, India and Cycle Pharmaceuticals Limited, a Limited Company having its principal offices at Cambridge, UK.
Cycle Pharmaceuticals Limited is one of the niche global pharmaceutical companies with unique products and sharp focus on key geographies like USA and Europe.
Under this agreement. Caplin Point shall be responsible for developing and manufacturing identified liquid injectable products whereas Cycle Pharmaceuticals Limited shall be holding this ANDA and commercialize the same in USA.
This is a product specific agreement for United States of America. Currently one product is featuring in the contract.
Caplin Point has already received milestone payment for one product and the product development cum dossier preparation have just commenced.
However, the Company will keep you updated on further developments including further financial impact from time to time. |
|
|